ArticleBMJ global health2023
Cost-effectiveness of measles and rubella elimination in low-income and middle-income countries.
Article in BMJ global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Seroprevalence of IgG Antibodies to Measles, Mumps, Rubella and Varicella in Adolescents with Documented Two-Dose MMR Vaccination: Cross-Sectional Study.Antibodies (Basel, Switzerland) · 2026Article
- Beyond elimination: reframing measles vaccination strategies.BMJ global health · 2026Article
- Completeness of MMR Vaccination and Durability of Vaccine-Induced Antibody Responses in Children with Inflammatory Bowel Disease.Biomedicines · 2026Article
- Cost-effectiveness and budget impact analyses of strategies to improve measles vaccination coverage in Kenya.PLOS global public health · 2026Article
- Measles and rubella: From global health challenges to advancements in molecular diagnostics in the elimination era.Molecular therapy. Nucleic acids · 2025Review
- Therapeutic Vaccines for Non-Communicable Diseases: Global Progress and China's Deployment Pathways.Vaccines · 2025Review
- Scoping Review of Current Costing Literature on Interventions to Reach Zero-Dose Children in Low- and Middle-Income Countries.Vaccines · 2024Article
- Congenital Rubella Syndrome Does Not Increase with Introduction of Rubella-Containing Vaccine.Vaccines · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundSince 2000, the incidence of measles and rubella has declined as measles-rubella (MR) vaccine coverage increased due to intensified routine immunisation (RI) and supplementary immunisation activities (SIAs). The World Health Assembly commissioned a feasibility assessment of eliminating measles and rubella. The objective of this paper is to present the findings of cost-effectiveness analysis (CEA) of ramping up MR vaccination with a goal of eliminating transmission in every country.
methodsWe used projections of impact of routine and SIAs during 2018-2047 for four scenarios of ramping up MR vaccination. These were combined with economic parameters to estimate costs and disability-adjusted life years averted under each scenario. Data from the literature were used for estimating the cost of increasing routine coverage, timing of SIAs and introduction of rubella vaccine in countries.
resultsThe CEA showed that all three scenarios with ramping up coverage above the current trend were more cost-effective in most countries than the 2018 trend for both measles and rubella. When the measles and rubella scenarios were compared with each other, the most cost-effective scenario was likely to be the most accelerated one. Even though this scenario is costlier, it averts more cases and deaths and substantially reduces the cost of treatment.
conclusionsThe Intensified Investment scenario is likely the most cost-effective of the vaccination scenarios evaluated for reaching both measles and rubella disease elimination. Some data gaps on costs of increasing coverage were identified and future efforts should focus on filling these gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.